Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Detail)

v3.19.2
Stockholders' Equity - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
May 10, 2018
May 09, 2018
Stockholders Equity [Line Items]              
Description of reverse stock split     At BIOLASE’s annual meeting of stockholders on May 9, 2018 (the “2018 Annual Meeting”), BIOLASE stockholders approved an amendment to BIOLASE’s Restated Certificate of Incorporation, as amended, to effect the Reverse Stock Split of BIOLASE common stock and on May 10, 2018, the Company filed an amendment (the “Amendment”) to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, effective as of 11:59 p.m. on May 10, 2018. The Amendment also reduced the authorized shares of common stock from 200,000,000 shares to 40,000,000 shares. Prior year share and per share amounts have been adjusted to reflect the impact of the Reverse Stock Split.        
Common stock, shares authorized 40,000   40,000   40,000 40,000,000 200,000,000
Compensation expense related to stock options $ 0.5 $ 0.6 $ 1.2 $ 1.3      
Total unrecognized compensation expense $ 1.6   $ 1.6        
Unrecognized share based compensation expense to be recognized over weighted-average period     2 years        
Outstanding stock options, RSUs and warrants excluded from diluted loss per share 5,700,000 3,800,000 5,700,000 3,800,000      
2002 Stock Incentive Plan              
Stockholders Equity [Line Items]              
Common stock authorized for issuance 3,100,000   3,100,000        
Common stock issued pursuant to options exercised     1,500,000        
Options and restricted stock units outstanding 1,600,000   1,600,000        
Options available for future grants 0   0        
2018 Long-Term Incentive Plan              
Stockholders Equity [Line Items]              
Common stock authorized for issuance 5,000,000   5,000,000        
Options and restricted stock units outstanding 1,400,000   1,400,000        
Options available for future grants 3,600,000   3,600,000